← Leaderboards
Nicholas David Cosford
Sanford Burnham Prebys Medical Discovery Institute
$46,036,569
Attributed
$73,112,737
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.3M · FY2007–25$20M$15M$10M$5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$73,112,737 · 16
By mechanism
U01$31,264,469 · 3
R01$21,818,228 · 7
U54$13,572,626 · 1
RF1$2,947,358 · 1
R33$1,443,000 · 1
R21$1,339,265 · 2
Top collaborators
- Gonul Velicelebi7 shared
- Robert M Anthenelli5 shared
- Athina Markou5 shared
- Andre Der-Avakian3 shared
- Darren Finlay3 shared
- Jose Luis Millan3 shared
- Jeffrey W Smith3 shared
- Selena E. Bartlett2 shared
Most similar at Sanford Burnham Prebys Medical Discovery Institute
Same institution · by research overlap
- Elena B Pasquale$23,453,916
- Gonul Velicelebi$8,970,452
- Yu Yamaguchi$22,864,918
- Darren Finlay$1,378,690
Others in their field
Top investigators on “Property”
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
Research focus
PropertyPharmaceutical PreparationsResponseDesignLeadIn VivoDrug KineticsChemistryIn VitroSmall MoleculeInnovationSeriesIn Vitro AssayMetabolismReceptorRattusBrainPreclinical StudyAbsorptionBaseDoseLaboratoriesResearch PersonnelLink
Grant awards (47)
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers$2,652,771
U01 · FY2025 · DA · contact PI
Fragment-Based Discovery of STEP Modulators in Alzheimer's Disease Administrative Supplement$111,976
RF1 · FY2025 · AG
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers$3,331,239
U01 · FY2024 · DA · contact PI
Fragment-based discovery of STEP modulators in Alzheimer's disease$2,835,382
RF1 · FY2024 · AG
Safety/Toxicology, ADME and CMC Activities to Support the Assessment of the mGlu2 PAM SBP-9330 in a Phase 2 Clinical Study in Smokers$3,064,047
U01 · FY2023 · DA · contact PI
Characterization, optimization, and development of dual mGlu2/3 positive allosteric modulators for opioid use disorder$6,445,203
R01 · FY2022 · DA · contact PI
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$3,560,198
U01 · FY2022 · DA · contact PI
Cancer Targets and Drug Discovery$246,572
T32 · FY2022 · CA · contact PI
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$4,154,854
U01 · FY2021 · DA · contact PI
Cancer Targets and Drug Discovery$253,774
T32 · FY2021 · CA · contact PI
Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction$3,703,043
U01 · FY2020 · DA · contact PI
Cancer Targets and Drug Discovery$227,445
T32 · FY2020 · CA · contact PI
Preclinical studies for the development of selective mGlu2 positive allosteric modulators to treat substance use disorders$4,332,196
U01 · FY2019 · DA · contact PI
Preclinical studies for the development of selective mGlu2 positive allosteric modulators to treat substance use disorders$3,819,904
U01 · FY2018 · DA · contact PI
Lead optimization of novel ML-IAP antagonists to treat lung cancer$974,339
R01 · FY2018 · CA · contact PI
Lead optimization of Novel mGlu2 Negative Allosteric Modulators$785,204
R01 · FY2018 · MH · contact PI
Preclinical studies for the development of selective mGlu2 positive allosteric modulators to treat substance use disorders$2,646,217
U01 · FY2017 · DA · contact PI
Lead optimization of novel ML-IAP antagonists to treat lung cancer$974,339
R01 · FY2017 · CA · contact PI
Lead optimization of Novel mGlu2 Negative Allosteric Modulators$785,204
R01 · FY2017 · MH · contact PI
Lead optimization of Novel mGlu2 Negative Allosteric Modulators$896,201
R01 · FY2016 · MH · contact PI
Lead optimization of novel ML-IAP antagonists to treat lung cancer$808,701
R01 · FY2016 · CA · contact PI
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN$755,282
R01 · FY2016 · CA · contact PI
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN$755,282
R01 · FY2015 · CA · contact PI
Lead Optimization of Novel Inhibitors of Tissue Non-specific Alkaline Phosphatase$726,119
R01 · FY2015 · AG · contact PI
Group II mGluR antagonists and negative modulators in depression$858,292
R01 · FY2014 · MH
Lead Optimization of Novel Inhibitors of the Thioesterase Domain of FASN$755,282
R01 · FY2014 · CA · contact PI
Lead Optimization of Novel Inhibitors of Tissue Non-specific Alkaline Phosphatase$752,413
R01 · FY2014 · AG · contact PI
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes$487,500
R33 · FY2014 · DA · contact PI
Group II mGluR antagonists and negative modulators in depression$830,492
R01 · FY2013 · MH
Lead Optimization of Novel Inhibitors of Tissue Non-specific Alkaline Phosphatase$752,413
R01 · FY2013 · AG · contact PI
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes$468,000
R33 · FY2013 · DA · contact PI
Chemistry$2,409,416
U54 · FY2012 · HG · contact PI
Group II mGluR antagonists and negative modulators in depression$872,101
R01 · FY2012 · MH
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes$487,500
R33 · FY2012 · DA · contact PI
Chemistry$4,516,698
U54 · FY2011 · HG · contact PI
Group II mGluR antagonists and negative modulators in depression$878,070
R01 · FY2011 · MH
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes$393,370
R21 · FY2011 · DA
Chemistry$2,247,863
U54 · FY2010 · HG · contact PI
Group II mGluR antagonists and negative modulators in depression$824,172
R01 · FY2010 · MH
Identifying Chemical Modulators of CRF-Binding Protein and CRF Receptor Complexes$423,032
R21 · FY2010 · DA
Optimization of EphA4 antagonists for CNS disorders$236,363
R21 · FY2010 · NS
Chemistry$2,267,151
U54 · FY2009 · HG · contact PI
Modulators of Metabotropic Glutamate Receptor Subtype 2 for Cocaine Dependence$468,423
R01 · FY2009 · DA · contact PI
Optimization of EphA4 antagonists for CNS disorders$286,500
R21 · FY2009 · NS
Chemistry$2,131,498
U54 · FY2008 · HG · contact PI
Modulators of Metabotropic Glutamate Receptor Subtype 2 for Cocaine Dependence$454,785
R01 · FY2008 · DA · contact PI
Modulators of Metabotropic Glutamate Receptor Subtype 2 for Cocaine Dependence$465,911
R01 · FY2007 · DA · contact PI